Contents
Part 1 · Preliminary
1Name#
This instrument is the National Health (Immunisation Program—Designated Vaccines) Determination 2026.
2Commencement#
(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
|---|---|---|
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 October 2026. | 1 October 2026 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
4Schedule 2#
Each instrument that is specified in Schedule 2 to this instrument is amended or repealed as set out in the applicable items in that Schedule, and any other item in that Schedule has effect according to its terms.
5Definitions#
In this instrument:
µg means microgram.
Aboriginal person means a person of the Aboriginal race of Australia.
CCID50 means cell culture infectious dose 50%, being the quantity of an infectious agent that when inoculated onto a number of susceptible cell cultures will infect 50% of the individual cultures.
FHA means filamentous haemagglutinin.
FIM 2+3 means fimbrial agglutinogens 2+3.
IU means International Unit.
medical risk condition: see section 6.
PFU means plaque forming units.
PRN means pertactin.
PT means pertussis toxoid.
severe immunocompromise means a severely immunocompromising condition as described in the chapter titled COVID-19 in the Australian Immunisation Handbook, published by the Department, as existing on 1 October 2026.
Note: The Australian Immunisation Handbook could in 2026 be viewed on the Department’s Immunisation Handbook website (https://immunisationhandbook.health.gov.au).
table item, in relation to Schedule 1, means an item of a table in a clause in Schedule 1.
TCID50 means tissue culture infectious dose 50%, being the quantity of an infectious agent that when inoculated onto a number of susceptible tissue cultures will infect 50% of the individual cultures.
Torres Strait Islander means a descendant of an Indigenous inhabitant of the Torres Strait Islands.
6Meaning of medical risk condition#
A medical risk condition is any of the following:
(a)functional or anatomical asplenia, including sickle cell disease, other haemoglobinopathies, congenital or acquired asplenia (e.g. splenectomy) or hyposplenia;
(b)immunocompromising conditions, including congenital or acquired immune deficiency including symptomatic IgG subclass or isolated IgA deficiency, haematological malignancies, solid organ transplant, haematopoietic stem cell transplant or HIV infection;
(c)chronic respiratory disease, including suppurative lung disease, bronchiectasis and cystic fibrosis or chronic lung disease of prematurity;
(d)chronic renal disease, including end stage renal disease (eGFR <15mL/min) or relapsing or persistent nephrotic syndrome;
(e)proven or presumptive cerebrospinal fluid leak;
(f)cochlear implants;
(g)intracranial shunts;
(h)previous episode of invasive pneumococcal disease;
(i)born less than 28 weeks gestation;
(j)trisomy 21;
(k)chronic heart disease, including cyanotic heart disease or heart failure.
Part 2 · Designated vaccines and circumstances
Division 1 · Designated vaccines
Division 2 · Circumstances
8Circumstances#
For the purposes of subsection 9B(5) of the Act, the circumstances in which a designated vaccine may be provided are those specified for the vaccine in:
(a)Schedule 1; or
(b)another section of this Division.
9Catch-up doses for persons less than 10 years old#
A circumstance for a designated vaccine is that:
(a)the table item in Schedule 1 that specifies the vaccine specifies circumstances in which the vaccine may be provided to a person specified in those circumstances to be an age that is no more than 4 years; and
(b)the person did not receive the vaccine at the specified age; and
(c)the person is less than 10 years old.
Example: A vaccine is intended to be provided for the immunisation of a person at 2 months, 4 months and 6 months old but the person does not receive the vaccine at those ages, the doses of vaccine may be provided at any time before the person turns 10 years old.
10Catch-up doses for persons at least 10 years but less than 20 years old#
A circumstance for a designated vaccine is that:
(a)the vaccine is specified in table item 101, 102, 106, 202, 219, 220, 221, 222, 223, 225 or 226 in Schedule 1; and
(b)the table item specifies circumstances in which the vaccine may be provided to a person specified in those circumstances to be a certain age; and
(c)the person did not receive the vaccine at the specified age nor in accordance with the circumstance specified in section 9; and
(d)the person is at least 10 years old but less than 20 years old.
Note: The designated vaccines covered by paragraph (a) are Boostrix, Adacel, Nimenrix, H-B-Vax II, M-M-R II, Priorix, Priorix-Tetra, ProQuad, IPOL, Varilrix and Varivax Refrigerated.
11Catch-up doses for visa-holders at least 20 years old#
A circumstance for a designated vaccine is that:
(a)the vaccine is specified in table item 101, 102, 202, 219, 220, 223, 225 or 226 in Schedule 1; and
(b)the table item specifies circumstances in which the vaccine may be provided to a person specified in those circumstances to be a certain age; and
(c)the person did not receive the vaccine at the specified age nor in accordance with the circumstance specified in section 9 or 10; and
(d)the person is at least 20 years old; and
(e)the person holds any of the following visas granted under the Migration Act 1958:
(i)Subclass 200 (Refugee) visa;
(ii)Subclass 201 (In-country Special Humanitarian) visa;
(iii)Subclass 202 (Global Special Humanitarian) visa;
(iv)Subclass 203 (Emergency Rescue) visa;
(v)Subclass 204 (Woman at Risk) visa.
Note: The designated vaccines covered by paragraph (a) are Boostrix, Adacel, H-B-Vax II, M-M-R II, Priorix, IPOL, Varilrix and Varivax Refrigerated.
Schedule 1 · Designated vaccines and circumstances
Note: See sections 7 and 8.
Part 1 · Bacterial vaccines
1Bacterial vaccines and circumstances#
Each item of the following table specifies:
(a)a bacterial vaccine; and
(b)circumstances in which the vaccine may be provided.
Note: Sections 9, 10 and 11 also specify circumstances in which certain vaccines may be provided.
| Bacterial vaccines and circumstances | ||||||
|---|---|---|---|---|---|---|
| Item | Column 1Disease | Column 2Brand | Column 3Formulation | Column 4Active ingredient and strength | Column 5Doses | Column 6Circumstances |
| 101 | Diphtheria, tetanus and pertussis (adult/adolescent) | Boostrix | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 2IU;(b) tetanus toxoid—not less than 20IU;(c) PT—8µg;(d) FHA—8µg;(e) PRN—2.5µg | One dose (booster) | Vaccine is provided to:(a) a person who is at least 10 years but less than 18 years old; or(b) a person who is pregnant. |
| 102 | Diphtheria, tetanus and pertussis (adult/adolescent) | Adacel | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 2IU;(b) tetanus toxoid—not less than 20IU;(c) PT—2.5µg;(d) FHA—5µg;(e) PRN—3µg;(f) FIM 2+3—5µg | One dose (booster) | Vaccine is provided to:(a) a person who is at least 10 years but less than 18 years old; or(b) a person who is pregnant. |
| 103 | Diphtheria, tetanus and pertussis (child) | Infanrix | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 30IU;(b) tetanus toxoid—not less than 40IU;(c) PT—25µg;(d) FHA—25µg;(e) PRN—8µg | One dose (booster) | Vaccine is provided to a person who is about 18 months old. |
| 104 | Diphtheria, tetanus and pertussis (child) | Tripacel | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 30IU;(b) tetanus toxoid—not less than 40IU;(c) PT—10µg;(d) FHA—5µg;(e) PRN—3µg;(f) FIM 2+3—5µg | One dose (booster) | Vaccine is provided to a person who is about 18 months old. |
| 105 | Haemophilus influenzae type b (Hib) (monovalent PRP-T) | ActHib or Hiberix | Refrigerated lyophilised preparation for injection (0.5mL) with separate diluent | Purified Hib capsular polysaccharide conjugated to tetanus toxoid—10µg | One dose (booster) | Vaccine is provided to:(a) a person who is about 18 months old; or(b) a person who:(i) is at least 5 years old; and(ii) has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; and(iii) did not receive childhood vaccinations; or(c) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan). |
| 106 | Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate | Nimenrix | Injection (0.5mL) | After reconstitution, each of the following:(a) Meningococcal polysaccharide - Serogroup A—5μg;(b) Meningococcal polysaccharide - Serogroup C—5μg;(c) Meningococcal polysaccharide - Serogroup W-135—5 μg;(d) Meningococcal polysaccharide - Serogroup Y—5μg.Each dose contains conjugated to tetanus toxoid carrier protein 44μg | As follows:(a) in the circumstances specified in paragraph (a), (b) or (f) of column 6—one dose;(b) primary doses in the circumstances specified in paragraph (c), (d) or (e) of column 6:(i) if at least 6 weeks but less than 6 months old at the start of the vaccine course–4 doses; or(ii) if at least 6 months but less than 12 months old at the start of the vaccine course–3 doses; or(iii) if at least 12 months old at the start of the vaccine course–2 doses;(c) booster doses in the circumstances specified in paragraph (c), (d) or (e) of column 6:(i) if less than 7 years old when primary doses completed—1 booster dose 3 years after completing primary doses, and 1 booster dose every 5 years after that; or(ii) if at least 7 years old when primary doses completed—1 booster dose every 5 years after completing primary doses | Vaccine is provided to:(a) a person who is 12 months old; or(b) a person who is at least 14 years but less than 20 years old; or(c) a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or(d) a person who has complement deficiency; or(e) a person who is undergoing treatment, or will commence treatment, with Soliris (eculizumab); or(f) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan). |
| 107 | Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine (Men ACWY-CRM) | Menveo | Injection (0.5mL) | Each of the following:(a) 10µg Meningococcal polysaccharide serogroup A conjugated to 16.7—33.3µg Corynebacterium diphtheriae CRM197 protein;(b) 5µg Meningococcal polysaccharide serogroup C conjugated to 7.1—12.5µg C. diphtheriae CRM197 protein;(c) 5µg Meningococcal polysaccharide serogroup W-135 conjugated to 3.3—8.3µg C. diphtheriae CRM197 protein;(d) 5µg Meningococcal polysaccharide serogroup Y conjugated to 5.6—10µg C. diphtheriae CRM197 protein | One dose | Vaccine is provided to:(a) a person who is at least 14 years but less than 17 years old as part of a school based program; or(b) a person who is at least 14 years but less than 19 years old who did not receive the vaccination as part of a school based program; or(c) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan). |
| 108 | Meningococcal Neisseria meningitidis, Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate serogroups A, C, W and Y | MenQuadfi | Injection (0.5mL) | Each of the following:(a) Meningococcal polysaccharide group A—10.0µg;(b) Meningococcal polysaccharide group C—10.0µg;(c) Meningococcal polysaccharide group Y—10.0µg;(d) Meningococcal polysaccharide group W-135—10.0µg.Each of the 4 polysaccharides is conjugated to tetanus toxoid (approximately 55µg/dose) | As follows:(a) in the circumstances specified in paragraph (a) or (b) of column 6—one dose;(b) in the circumstances specified in paragraph (c), (d) or (e) of column 6:(i) primary doses—2 doses; and(ii) booster doses if less than 7 years old when primary doses completed—1 booster dose 3 years after completing primary doses, and 1 booster dose every 5 years after that; and(iii) booster doses if at least 7 years old when primary doses completed—1 booster dose every 5 years after completing primary doses;(c) in the circumstances specified in paragraph (f) of column 6:(i) one dose; and(ii) booster doses—one dose every 5 years after that | Vaccine is provided to:(a) a person who is 12 months old; or(b) a person who is at least 14 years but less than 20 years old; or(c) a person who is at least 12 months old and has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or(d) a person who is at least 12 months old and has complement deficiency; or(e) a person who is at least 12 months old and is undergoing treatment, or will commence treatment, with Soliris (eculizumab); or(f) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan). |
| 109 | Pneumococcal (conjugate, 13 valent) | Prevenar 13 | Injection (0.5mL) | Polysaccharides of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F—4.4μg of serotype 6B and 2.2µg of each other serotype | As follows:(a) maximum of 3 primary doses in the circumstances specified in paragraph (a) of column 6, as follows:(i) one dose given at about 2 months old;(ii) one dose given at about 4 months old;(iii) one dose given at about 12 months but less than 24 months old;(b) in the circumstances specified in paragraph (c) of column 6—one dose;(c) booster dose in the circumstances specified in paragraph (b), (d), (e), (f), (g) or (h) of column 6—one dose | Vaccine is provided to:(a) a person who is about:(i) 2 months old; or(ii) 4 months old; or(iii) 12 months but less than 24 months old; or(b) a person who:(i) is about 6 months old; and(ii) lives in Queensland, Western Australia, South Australia or the Northern Territory; and(iii) is an Aboriginal person or Torres Strait Islander; or(c) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab; or(d) a person who is about 6 months old and has at least one medical risk condition; or(e) a person who is at least 12 months but less than 5 years old and has been newly diagnosed with at least one medical risk condition; or(f) a person who is at least 5 years old and has been newly diagnosed with at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h); or(g) a person who is at least 50 years old and is an Aboriginal person or Torres Strait Islander; or(h) a person who is at least 70 years old. |
| 110 | Pneumococcal (conjugate, 20-valent) | Prevenar 20 | Injection (0.5mL) | Polysaccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to Corynebacterium diphtheriae CRM197 protein | Maximum of 3 doses, as follows:(a) one dose given at about 2 months old;(b) one dose given at about 4 months old;(c) one dose given at about 12 months but less than 24 months old | Vaccine is provided to a person who is:(a) about 2 months old; or(b) about 4 months old; or(c) about 12 months old but less than 24 months old |
| 111 | Pneumococcal (conjugate, 20-valent) | Prevenar 20 | Injection (0.5mL) | Polysaccharides of the capsular antigens of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to Corynebacterium diphtheriae CRM197 protein | Maximum of one dose | Vaccine is provided to:(a) a person who is about 6 months old and:(i) is an Aboriginal person or Torres Strait Islander; or(ii) has at least one medical risk condition; or(b) a person who:(i) is at least 12 months but less than 5 years old; and(ii) has been newly diagnosed with at least one medical risk condition; or(c) a person who:(i) is at least 5 years but less than 18 years old; and(ii) has been newly diagnosed with at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h). |
| 112 | Pneumococcal (conjugate, 21 valent) | Capvaxive | Injection (0.5mL) | 84µg of pneumococcal purified capsular polysaccharide antigen (4µg each of polysaccharide serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, deOAc15B, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B) conjugated to approximately 65µg of diphtheria Corynebacterium diphtheriae CRM197 protein | Maximum of one dose | Vaccine is provided to:(a) a person who is at least 18 years old and has been diagnosed with:(i) at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h); or(ii) chronic liver disease; or(iii) chronic obstructive pulmonary disease; or(b) a person who:(i) is at least 25 years old; and(ii) is an Aboriginal person or Torres Strait Islander; or(c) a person who is at least 65 years old; or(d) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan). |
| 113 | Pneumococcal (polysaccharide, 23-valent) | PneumoVax 23 | Injection (0.5mL) | Polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F—25µg of each serotype | As follows:(a) in the circumstances specified in paragraph (a) of column 6—2 doses;(b) in the circumstances specified in paragraph (b), (c), (d) or (e) of column 6:(i) first dose—one dose; and(ii) second dose—one dose given at least 5 years after the first dose | Vaccine is provided to:(a) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal haemoglobinuria who have an inadequate clinical response or are intolerant to treatment with eculizumab or ravulizumab; or(b) a person who:(i) is at least 4 years but less than 6 years old; and(ii) has at least one medical risk condition; or(c) a person who:(i) is at least 5 years old; and(ii) has been newly diagnosed with at least one of the medical risk conditions mentioned in paragraphs 6(a) to (h); or(d) a person who:(i) is at least 4 years but less than 6 years old; and(ii) lives in Queensland, Western Australia, South Australia or the Northern Territory; and(iii) is an Aboriginal person or Torres Strait Islander; or(e) a person who:(i) is at least 50 years old; and(ii) is an Aboriginal person or Torres Strait Islander; and(iii) has not received a dose under paragraph (c). |
| 114 | Multicomponent meningococcal group B (4CMenB) | Bexsero | Injection (0.5mL) | Each of the following:(a) Neisseria meningitidis serogroup B Neisseria heparin binding antigen fusion protein—50µg;(b) Neisseria meningitidis serogroup B Neisseria adhesion A protein—50µg;(c) Neisseria meningitidis serogroup B factor H binding protein fusion protein—50µg;(d) outer membrane vesicles from Neisseria meningitidis serogroup B strain NZ98/254 (measured as amount of total protein containing the PorA P1.4)—25µg | As follows:(a) in the circumstances specified in paragraph (a) of column 6—2 doses provided at least 8 weeks apart;(b) in the circumstances specified in paragraph (c) of column 6—as follows:(i) if at least 2 months old at the start of the vaccine course—3 primary doses at least 8 weeks apart, and one booster dose when at least 12 months old;(ii) if less than 2 years old at the start of the vaccine course—3 primary doses at least 8 weeks apart, and one booster dose given at least 6 months after completing primary doses;(c) in the circumstances specified in paragraph (d) of column 6—as follows:(i) if at least 2 months old at the start of the vaccine course—2 primary doses at least 8 weeks apart, and one booster dose when at least 12 months old;(ii) if less than 2 years old at the start of the vaccine course and has not received a dose under subparagraph (i)—2 primary doses at least 8 weeks apart, and one booster dose given at least 8 months after completing primary doses;(d) in the circumstances specified in paragraph (b), (e) or (f) of column 6—as follows:(i) if at least 6 weeks but less than 6 months old at the start of the vaccine course—3 primary doses at least 8 weeks apart, and one booster dose when at least 12 months old;(ii) if at least 6 months but less than 12 months old at the start of the vaccine course—2 primary doses at least 8 weeks apart, and one booster dose when at least 12 months old;(iii) if at least 12 months old at the start of the vaccine course—2 primary doses at least 8 weeks apart | Vaccine is provided to:(a) a person who is undergoing treatment, or will commence treatment, with Empavali (pegcetacoplan); or(b) a person who is undergoing treatment, or will commence treatment, with Soliris (eculizumab); or(c) a person who is an Aboriginal person or Torres Strait Islander, and has any of the following medical conditions known to increase the risk of invasive meningococcal disease:(i) defects in, or deficiency of, complement components, including factor H, factor D or properdin deficiency;(ii) current or future treatment with eculizumab (a monoclonal antibody directed against complement component C5);(iii) functional or anatomical asplenia, including sickle cell disease or other haemoglobinopathies, and congenital or acquired asplenia;(iv) HIV, regardless of disease stage or CD4+ cell count;(v) haematopoietic stem cell transplant; or(d) a person who:(i) is an Aboriginal person or Torres Strait Islander; and(ii) is not covered by paragraph (c); or(e) a person who has congenital or acquired asplenia (e.g. splenectomy) or hyposplenia; or(f) a person who has complement deficiency. |
Part 2 · Viral vaccines
2Viral vaccines and circumstances#
Each item of the following table specifies:
(a)a viral vaccine; and
(b)circumstances in which the vaccine may be provided.
Note: Sections 9, 10 and 11 also specify circumstances in which certain vaccines may be provided.
| Viral vaccines and circumstances | ||||||
|---|---|---|---|---|---|---|
| Item | Column 1Disease | Column 2Brand | Column 3Formulation | Column 4Active ingredient and strength | Column 5Doses | Column 6Circumstances |
| 201 | Hepatitis A (monovalent) | VAQTA Paediatric/ Adolescent | Injection (0.5mL) | Hepatitis A virus protein—25 units | 2 doses given 6 months apart | Vaccine is provided to a person who:(a) is an Aboriginal person or Torres Strait Islander; and(b) is at least 1 year but less than 5 years old; and(c) lives in Queensland, Western Australia, South Australia or the Northern Territory. |
| 202 | Hepatitis B (monovalent adult) | H-B-Vax II | Vial for injection (1mL) | Hepatitis B surface antigen protein—10µg | 2 doses given between 4 and 6 months apart | Vaccine is provided to a person who is at least 10 years but less than 14 years old. |
| 203 | Hepatitis B (monovalent paediatric) | Engerix-B | Vial for injection (0.5mL) | Hepatitis B surface antigen protein—10µg | As follows:(a) in the circumstances specified in paragraph (a) of column 6—one dose;(b) in the circumstances specified in paragraph (b) of column 6:(i) first dose—one dose; and(ii) second dose—one dose given 1 month after the first dose; and(iii) third dose—one dose given 5 months after the second dose | Vaccine is provided to:(a) a newborn infant as soon as practicable after birth but no later than 7 days after birth; or(b) a person who:(i) is at least 10 years but less than 14 years old; and(ii) has not received a Hepatitis B containing vaccine. |
| 204 | Hepatitis B (monovalent paediatric) | H-B-Vax II | Vial for injection (0.5mL) | Hepatitis B surface antigen protein—5µg | One dose | Vaccine is provided to a newborn infant as soon as practicable after birth but no later than 7 days after birth. |
| 205 | Influenza | Influvac or Fluarix | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years old—one dose per calendar year.For persons who are at least 6 months but less than 3 years old, the dose is 0.25mL | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is:(i) an Aboriginal person or Torres Strait Islander; and(ii) at least 6 months but less than 5 years old, or at least 15 years old; or(c) is at least 6 months old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(d) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(e) is pregnant. | |
| 206 | Influenza | Fluarix Tetra | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or(c) is at least 6 months but less than 5 years old; or(d) is at least 6 months old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(f) is pregnant. | |
| 207 | Influenza | FluQuadri | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or(c) is at least 6 months but less than 5 years old; or(d) is at least 6 months old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(f) is pregnant. | |
| 208 | Influenza | Afluria Quad | Injection (0.5mL) | One dose per calendar year | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is an Aboriginal person or Torres Strait Islander and is at least 5 years old; or(c) is at least 5 years old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(d) is pregnant. | |
| 209 | Influenza | Fluzone High Dose | Injection (0.5mL) | One dose per calendar year | Vaccine is provided to a person who is at least 65 years old. | |
| 210 | Influenza | Fluad | Injection (0.5mL) | One dose per calendar year | Vaccine is provided to a person who is at least 65 years old. | |
| 211 | Influenza | VaxiGrip Tetra | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or(c) is at least 6 months but less than 5 years old; or(d) is at least 6 months old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(f) is pregnant. | |
| 212 | Influenza | Fluad Quad | Injection (0.5mL) | One dose per calendar year | Vaccine is provided to a person who is at least 65 years old. | |
| 213 | Influenza | FluQuadri Junior | Injection (0.25mL) | As follows:(a) 2 doses at least 1 month apart;(b) one dose in each subsequent calendar year | Vaccine is provided to a person who:(a) is at least 6 months but less than 3 years old; and(b) is an Aboriginal person or Torres Strait Islander, or:(i) has cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure; or(ii) has a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma; or(iii) has another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment); or(iv) has a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders; or(v) has impaired immunity, including HIV infection; or(vi) is receiving long-term aspirin therapy. | |
| 214 | Influenza | Flucelvax Quad | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years but less than 65 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 6 months but less than 5 years old; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months but less than 65 years old; or(c) is at least 6 months but less than 65 years old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(d) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(e) is pregnant. | |
| 215 | Influenza | Vaxigrip | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or(c) is at least 6 months but less than 5 years old; or(d) is at least 6 months old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(f) is pregnant. | |
| 216 | Influenza | Fluzone | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 65 years; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months old; or(c) is at least 6 months but less than 5 years old; or(d) is at least 6 months old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(e) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(f) is pregnant. | |
| 217 | Influenza | Flucelvax | Injection (0.5mL) | As follows:(a) for a person who is at least 6 months but less than 9 years old:(i) 2 doses at least 1 month apart; and(ii) one dose in each subsequent calendar year;(b) for a person who is at least 9 years but less than 65 years old—one dose per calendar year. | Vaccine is provided to a person who:(a) is at least 6 months but less than 5 years old; or(b) is an Aboriginal person or Torres Strait Islander and is at least 6 months but less than 65 years old; or(c) is at least 6 months but less than 65 years old and has any of the following:(i) cardiac disease, including cyanotic congenital heart disease, coronary artery disease or congestive heart failure;(ii) a chronic respiratory disease, including suppurative lung disease, bronchiectasis, cystic fibrosis, chronic obstructive pulmonary disease, chronic emphysema or severe asthma;(iii) another chronic illness requiring regular medical follow-up or hospitalisation in the preceding 12 months, including diabetes mellitus, chronic metabolic diseases, chronic renal failure, haemoglobinopathies or impaired immunity (including drug-induced immune impairment);(iv) a chronic neurological condition, including multiple sclerosis, spinal cord injuries, seizure disorders or other neuromuscular disorders;(v) impaired immunity, including HIV infection; or(d) is at least 6 months but less than 11 years old and is receiving long-term aspirin therapy; or(e) is pregnant. | |
| 218 | Influenza | Flublok | Injection (0.5mL) | One dose per calendar year. | Vaccine is provided to a person who is at least 65 years old. | |
| 219 | Measles, mumps and rubella | M-M-R II | Refrigerated lyophilised preparation for injection (0.5mL) | Each of the following live attenuated viruses:(a) measles virus (Edmonston strain)—1000 TCID50;(b) mumps virus (Jeryl Lynn strain)—5000 TCID50;(c) rubella virus (Wistar RA 27/3 strain)—1000 TCID50 | As follows:(a) in the circumstances specified in paragraph (a) of column 6—one dose;(b) in the circumstances specified in paragraph (b) of column 6—one dose;(c) in the circumstances specified in paragraph (c) of column 6—one dose | Vaccine is provided to a person who is:(a) about 12 months old; or(b) about 18 months old if given concurrently with a monovalent varicella vaccine; or(c) about 4 years old if the person was not given either of the following at about 18 months old:(i) a dose in the circumstances specified in paragraph (b);(ii) a measles, mumps, rubella and varicella vaccine. |
| 220 | Measles, mumps and rubella | Priorix | Refrigerated lyophilised preparation for injection (0.5mL) | Each of the following live attenuated viruses:(a) measles virus (Schwarz strain)—103.0 CCID50;(b) mumps virus (RIT 4385 strain derived from the Jeryl Lynn strain)—103.7 CCID50;(c) rubella virus (Wistar RA 27/3 strain)—103.0 CCID50 | As follows:(a) in the circumstances specified in paragraph (a) of column 6—one dose;(b) in the circumstances specified in paragraph (b) of column 6—one dose;(c) in the circumstances specified in paragraph (c) of column 6—one dose | Vaccine is provided to a person who is:(a) about 12 months old; or(b) about 18 months old if given concurrently with a monovalent varicella vaccine; or(c) about 4 years old if the person was not given either of the following at about 18 months old:(i) a dose in the circumstances specified in paragraph (b);(ii) a measles, mumps, rubella and varicella vaccine. |
| 221 | Measles, mumps, rubella and varicella | Priorix-Tetra | Powder for injection vial with diluent syringe (0.5mL) | Each of the following live attenuated viruses:(a) measles virus (Schwarz strain)—103.0 CCID50;(b) mumps virus (RIT 4385 strain derived from Jeryl Lynn strain)—104.4 CCID50;(c) rubella virus (Wistar RA 27/3 strain)—103.0 CCID50;(d) varicella virus (Oka strain)—103.3 PFU | One dose | Vaccine is provided to a person who is about 18 months old. |
| 222 | Measles, mumps, rubella and varicella | ProQuad | Injection (0.5mL) | Each of the following live attenuated viruses:(a) measles virus derived from Enders’ attenuated Edmonston strain—103.0 TCID50;(b) mumps virus (Jeryl Lynn™ (B Level) strain)—104.3 TCID50;(c) rubella virus (Wistar RA 27/3 strain)—103.0 TCID50;(d) Varicella-zoster virus (Oka/Merck strain)—103.99 PFU | One dose | Vaccine is provided to a person who is about 18 months old. |
| 223 | Poliomyelitis | IPOL | Injection (0.5mL) | Each of the following killed whole polioviruses:(a) type 1 (Mahoney)—40 D-antigen units;(b) type 2 (MEF-1)—8 D-antigen units;(c) type 3 (Saukett)—32 D-antigen units | As follows:(a) at about 2 months old—one dose;(b) at about 4 months old—one dose;(c) at about 6 months old—one dose;(d) at about 4 years old—one dose | Vaccine is provided to a person:(a) who is about:(i) 2 months old; or(ii) 4 months old; or(iii) 6 months old; or(iv) 4 years old; and(b) if all other vaccines containing poliovirus are unsuitable. |
| 224 | BNT162b2 mRNA COVID-19 | Comirnaty | Injection (0.3mL) | SARS-CoV-2 spike protein (mRNA)—30µg | As follows:(a) in the circumstances specified in paragraph (a), (b) or (c) of column 6—one dose per calendar year;(b) in the circumstances specified in paragraph (d) of column 6—2 doses per calendar year | Vaccine is provided to:(a) a person who:(i) is at least 18 years but less than 65 years old; and(ii) has a severe immunocompromise; or(b) a person who is at least 65 years but less than 75 years old; or(c) a person who:(i) is an Aboriginal person or Torres Strait Islander; and(ii) is at least 50 years but less than 75 years old; or(d) a person who is at least 75 years old. |
| 225 | Varicella | Varilrix | Refrigerated lyophilised preparation for injection (0.5mL) | Live attenuated Oka strain of the varicella-zoster virus—103.3 PFU | One dose | Vaccine is provided to a person who:(a) is about 18 months old; or(b) is at least 10 years but less than 14 years old, and has not had varicella nor been given a varicella vaccine. |
| 226 | Varicella | Varivax Refrigerated | Refrigerated lyophilised preparation for injection (0.5mL) | Live attenuated Oka/Merck strain of the varicella-zoster virus—at least 1350 PFU | One dose | Vaccine is provided to a person who:(a) is about 18 months old; or(b) is at least 10 years but less than 14 years old, and has not had varicella nor been given a varicella vaccine. |
| 227 | Herpes zoster (shingles) | Shingrix | Powder and suspension for injection (0.5mL) | Recombinant varicella zoster virus glycoprotein E antigen (AS01B Adjuvanted)—50µg | As follows:(a) if a person is immunodeficient, immunosuppressed or likely to become immunosuppressed due to a known disease or therapy—2 primary doses given between 1 and 2 months apart;(b) otherwise—2 primary doses given between 2 and 6 months apart | Vaccine is provided to a person who:(a) is at least 65 years old; or(b) is at least 50 years old and is an Aboriginal person or Torres Strait Islander; or(c) is at least 18 years old and is considered at increased risk of herpes zoster due to an underlying condition, including any of the following:(i) acute haematological malignancies such as acute leukaemia or aggressive lymphomas;(ii) chronic haematological malignancies, such as the following:(A) myelodysplastic syndromes;(B) chronic myeloproliferative disorders;(C) lymphoproliferative malignancies;(D) plasma cell dyscrasias which includes myeloproliferative neoplasms, chronic lymphocytic leukaemia, indolent non-Hodgkin lymphoma or multiple myeloma;(iii) human immunodeficiency virus infection with CD4+ cell count <200/µL;(iv) inborn errors of immunity with ongoing functional deficits, including any of the following:(A) humoral e.g. X-linked agammaglobulinemia;(B) combined defects, such as severe combined immunodeficiency;(C) phagocytic disorders, such as chronic granulomatous disease;(D) other inborn errors of immunity except complement disorders, hereditary angioedema and IgA deficiency;(v) stage 5 kidney disease or on dialysis; or(d) is at least 18 years old and is considered at increased risk of herpes zoster due to malignancy, autoimmune or inflammatory conditions receiving immunomodulatory or immunosuppressive treatments, including any of the following:(i) cellular therapies, whether received currently or within the previous 24 months, including any of the following:(A) autologous haematopoietic stem cell transplant;(B) allogeneic haematopoietic stem cell transplant, including ongoing graft versus host disease with immunosuppressive therapy, where a person is considered high risk beyond a 24 month period;(C) chimeric antigen receptor T-cell therapy;(ii) B and T-cell targeted monoclonal antibody therapies, whether received currently or within the last 6 months, including any of the following:(A) anti-CD20;(B) anti B-cell activating factor;(C) anti-CD52;(D) anti-thymocyte globulin;(iii) conventional chemotherapy for:(A) treatment of haematological malignancy; or(B) solid organ tumours, whether received currently or within the last 6 months;(iv) immunosuppressive therapy to prevent organ rejection prior to or following solid organ transplantation, whether received currently or within the last 6 months;(v) conventional immunosuppressive agents, whether received currently or within the last 6 months, including any of the following:(A) high dose methotrexate ≥20mg per week (oral and subcutaneous);(B) azathioprine ≥3.0mg/kg/day;(C) 6-mercaptopurine ≥1.5mg/kg/day;(D) mycophenolate ≥1g/day;(E) cyclophosphamide;(F) systemic calcineurin inhibitors such as tacrolimus or cyclosporin;(G) mTOR inhibitors;(H) purine analogues, such as cladribine;(vi) biologic therapies, whether received currently or within the last 6 months, not including lower risk biologics such as anti-integrins including natalizumab and vedolizumab, anti-IgE antibodies, anti-complement antibodies and lower risk interleukin (IL) inhibitors, anti-IL17 antibodies, anti-IL12/23 antibodies, anti-IL23 antibodies, and anti-IL31 antibodies, but including any of the following:(A) tumour necrosis factor inhibitors;(B) T-cell co-stimulation modulators such as Abatacept;(C) soluble TNF receptors;(D) type I interferon receptor inhibitors;(E) proteasome inhibitors;(F) IL inhibitors, whether received currently or within the last 6 months, including anti-IL1 antibodies, anti-IL4/13 antibodies, anti-IL5 antibodies, anti-IL6 antibodies and IL-6 receptor inhibitors;(vii) immunomodulatory drugs, whether received currently or within the last 6 months, including sphingosine-1-phosphate receptor modulators;(viii) oral small molecule targeted therapies, whether received currently or within the last 6 months, including any of the following:(A) bruton’s tyrosine kinase inhibitors;(B) janus kinase inhibitors;(C) BCR-ABL inhibitors. |
| 228 | Human papillomavirus (HPV) (9-valent) | Gardasil 9 | Injection (0.5mL) | Each of the following:(a) HPV 6 L1 protein—30μg;(b) HPV 11 L1 protein—40μg;(c) HPV 16 L1 protein—60μg;(d) HPV 18 L1 protein—40μg;(e) HPV 31 L1 protein—20μg;(f) HPV 33 L1 protein—20μg;(g) HPV 45 L1 protein—20μg;(h) HPV 52 L1 protein—20μg;(i) HPV 58 L1 protein—20μg | As follows:(a) in the circumstances specified in paragraph (a) or (b) of column 6—one dose;(b) in the circumstances specified in paragraph (c) of column 6—3 doses given between 6 and 12 months apart | Vaccine is provided to a person who:(a) is at least 12 years but less than 14 years old; or(b) is at least 12 years but less than 26 years old and has not received a single dose of Human papillomavirus vaccine; or(c) is at least 12 years but less than 26 years old and has impaired immunity. |
| 229 | Rotavirus | Rotarix | Oral suspension (1.5mL) in oral applicator | Human rotavirus vaccine, live attenuated, RIX 4414 strain (G1P[8])—not less than 106 CCID50 | 2 doses as follows:(a) first dose given between 6 and 14 weeks old;(b) second dose given between 14 and 24 weeks old | Vaccine is provided to a person who is about:(a) 2 months old; or(b) 4 months old. |
| 230 | Rotavirus | RotaTeq | Oral solution (2.0mL) | Live pentavalent reassortant vaccine containing each of the following:(a) G1—2.2 x 106 IU;(b) G2—2.8 x 106 IU;(c) G3—2.2 x 106 IU;(d) G4—2.0 x 106 IU;(e) P1 (8)—2.3 x 106 IU | 3 doses as follows:(a) first dose given between 6 and 14 weeks old;(b) second dose given between 14 and 24 weeks old;(c) third dose given before 32 weeks old | Vaccine is provided to a person who is about:(a) 2 months old; or(b) 4 months old; or(c) 6 months old. |
| 231 | Respiratory syncytial virus (RSV) stabilised prefusion F subunit | Abrysvo | Injection (0.5mL) | stabilised prefusion F proteins (60µg RSV-A and 60µg RSV-B antigens)—120µg | One dose:(a) between 28 and 36 weeks gestation; or(b) after 36 weeks gestation if vaccination is 2 weeks prior to expected date of birth. | Vaccine is provided to a person who is pregnant. |
| 232 | Respiratory syncytial virus (RSV) stabilised prefusion F protein (AS01E adjuvanted) | Arexvy | Injection (0.5mL) | recombinant respiratory syncytial virus pre-fusion F protein (RSVPreF3) antigen adjuvanted with AS01E—120μg | One dose | Vaccine is provided to a person who:(a) is at least 75 years old; or(b) is an Aboriginal person or Torres Strait Islander and is at least 60 years old. |
Part 3 · Combined bacterial and viral vaccines
3Combined bacterial and viral vaccines and circumstances#
Each item of the following table specifies:
(a)a combined bacterial and viral vaccine; and
(b)circumstances in which the vaccine may be provided.
Note: Sections 9, 10 and 11 also specify circumstances in which certain vaccines may be provided.
| Combined bacterial and viral vaccines and circumstances | ||||||
|---|---|---|---|---|---|---|
| Item | Column 1Disease | Column 2Brand | Column 3Formulation | Column 4Active ingredient and strength | Column 5Doses | Column 6Circumstances |
| 301 | Diphtheria, tetanus, pertussis and poliomyelitis | Infanrix-IPV | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 30IU;(b) tetanus toxoid—not less than 40IU;(c) PT—25µg;(d) FHA—25µg;(e) PRN—8µg;(f) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units;(g) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units;(h) inactivated poliovirus type 3 (Saukett)—32 D-antigen units | Maximum of 4 doses as follows:(a) one dose given at about 2 months old;(b) one dose given at about 4 months old;(c) one dose given at about 6 months old;(d) one dose given at the age described in paragraph (d) of column 6 | Vaccine is provided to a person who is:(a) about 2 months old; or(b) about 4 months old; or(c) about 6 months old; or(d) at least 3 years and 6 months old and less than 5 years old. |
| 302 | Diphtheria, tetanus, pertussis and poliomyelitis | Quadracel | Vial for injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 30IU;(b) tetanus toxoid—not less than 40IU;(c) PT—20µg;(d) FHA—20µg;(e) PRN—3µg;(f) FIM 2+3—5µg;(g) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units;(h) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units;(i) inactivated poliovirus type 3 (Saukett)—32 D-antigen units | Maximum of 4 doses as follows:(a) one dose given at about 2 months old;(b) one dose given at about 4 months old;(c) one dose given at about 6 months old;(d) one dose given at the age described in paragraph (d) of column 6 | Vaccine is provided to a person who is:(a) about 2 months old; or(b) about 4 months old; or(c) about 6 months old; or(d) at least 3 years and 6 months old and less than 5 years old. |
| 303 | Diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b (Hib) | Infanrix-Hexa | Injection (0.5mL) combination pack | Each of the following:(a) diphtheria toxoid—not less than 30IU;(b) tetanus toxoid—not less than 40IU;(c) PT—25µg;(d) FHA—25µg;(e) PRN—8µg;(f) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units;(g) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units;(h) inactivated poliovirus type 3 (Saukett)—32 D-antigen units;(i) recombinant hepatitis B surface antigen—10µg;(j) purified Hib capsular polysaccharide conjugated to tetanus toxoid—10µg | Maximum of 3 doses as follows:(a) one dose given at about 2 months old;(b) one dose given at about 4 months old;(c) one dose given at about 6 months old | Vaccine is provided to a person who is:(a) about 2 months old; or(b) about 4 months old; or(c) about 6 months old. |
| 304 | Diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b (Hib) | Hexaxim | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 20IU;(b) tetanus toxoid—not less than 40IU;(c) PT—25µg;(d) FHA—25µg;(e) inactivated poliovirus type1 (Mahoney)—40 D-antigen units;(f) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units;(g) inactivated poliovirus type 3 (Saukett)—32 D-antigen units;(h) recombinant hepatitis B surface antigen—10µg;(i) Hib polysaccharide (Polyribosylribitol Phosphate)—12µg;(j) Hib polysaccharide conjugated to tetanus protein—22-36µg | Maximum of 3 doses as follows:(a) one dose given at about 2 months old;(b) one dose given at about 4 months old;(c) one dose given at about 6 months old | Vaccine is provided to a person who is:(a) about 2 months old; or(b) about 4 months old; or(c) about 6 months old. |
| 305 | Diphtheria, tetanus, pertussis and poliomyelitis, hepatitis B, and Haemophilus influenzae type b (DTPa-HB-IPV-Hib) | Vaxelis | Injection (0.5mL) | Each of the following:(a) diphtheria toxoid—not less than 20IU;(b) tetanus toxoid—not less than 40IU;(c) PT—20µg;(d) FHA—20µg;(e) PRN—3µg;(f) FIM—3µg;(g) Hepatitis B surface antigen—10µg;(h) inactivated poliovirus type 1 (Mahoney)—40 D-antigen units;(i) inactivated poliovirus type 2 (MEF-1)—8 D-antigen units;(j) inactivated poliovirus type 3 (Saukett)—32 D-antigen units;(k) hepatitis B surface antigen—10µg;(l) Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate)—3µg;(m) Conjugated to meningococcal protein2—50µg | Maximum of 3 doses as follows:(a) one dose given at about 2 months old;(b) one dose given at about 4 months old;(c) one dose given at about 6 months old | Vaccine is provided to a person who is:(a) about 2 months old, and not less than 6 weeks old; or(b) about 4 months old; or(c) about 6 months old. |
Schedule 2 · Repeals
National Health (Immunisation Program — Designated Vaccines) Determination 2014 (No.1)#
1 The whole of the instrument
Repeal the instrument.
Sourced from the Federal Register of Legislation at legislation.gov.au, © Commonwealth of Australia, licensed under CC BY 4.0. Compilations may have been reformatted.